Stem cells and cancer
著者
書誌事項
Stem cells and cancer
(Cancer drug discovery and development)
Humana, c2009
- : hbk
大学図書館所蔵 全2件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Significance of Stem Cells to Tumor Development
Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease.
This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize 'side populations.' Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come.
Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.
Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.
目次
Table of Contents
Introduction - Cancer Stem Cells vs. Normal Stem Cells
Rebecca Bagley, MS, Genzyme Corporation
Chapter 1: Stem Cell Microenvironment - Hematopoietic Stem Cells
Linheng Li, PhD, Stowers Institute for Medical Research
Tannishtha Reya, PhD, Duke University Medical Center
David Scadden, MD, Center for Regenerative Medicine, Mass General Hospital
Sean Morrison, PhD, University of Michigan Medical School
Chapter 2: Tumor Niche/Microenvironment - Mesenchymal Stem Cells
Paul Simmons, PhD, University of Texas Health Science Center
Ajeeta Dash, PhD, Genzyme Corporation
Chapter 3: Cancer Stem Cells - Brain Tumors
Peter Dirks, PhD, MD, University of Toronto Hospital for Sick Children
Jeremey Rich, MD, Duke University Medical Center
Nobuko Uchida, PhD, Stem Cells, Inc.
Sheila Singh, MD, University of Toronto Hospital for Sick Children
Chapter 4: Cancer Stem Cells - Breast Carcinoma
Jane Visvader, PhD, Victorian Breast Cancer Research Consortium
Max Wicha, MD, University of Michigan Comprehensive Cancer Center
Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute
Connie Eaves, PhD, British Columbia Cancer Research Centre
Chapter 5: Cancer Stem Cells - Lung Cancers
Carla Bender Kim, PhD, Children's Hospital/Harvard University
Joan Schiller, MD, Southwestern Medical School/Simmons Comprehensive Cancer Center
Jaclyn Hung, PhD, British Columbia Cancer Research Centre
Chapter 6: Cancer Stem Cells - Pancreatic Cancer
Diane Simeone, MD, University of Michigan Medical Center
Chapter 7: Cancer Stem Cells - Ovarian
Paul Szotek, MD, Mass General Hospital, Harvard Medical School
Chapter 8: Cancer Stem Cells - Colon
Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute
Hans Clevers,MD/PhD, Netherlands Institute for Developmental Biology
Chapter 9: Cancer Stem Cells - Prostate Cancer
Owen Witte/Susan Kasper
Chapter 10: Epidermal Stem Cells
Elaine Fuchs, PhD, Rockefeller University
Fiona Watt, PhD, Cancer Resarch UK London, Cambridge Institute
Chapter 11: Hematopoietic Stem Cells in Blood Cancers: Leukemia / Myeloma / Lymphoma
Catriona Jamieson, MD/PhD, University of California Medical Center
Daniel Tenen, MD, Beth Israel Deaconess Medical Center, Harvard Medical School
Dominique Bonnet, PhD, London Research Institute
Michael Becker, MD, University of Rochester Medical Center
John Dick, PhD, Toronto General Research Institute
Frederick Alt, PhD, Howard Hughes Medical Institute
Michael Cleary, MD, Stanford University School of Medicine
Irving Weissman, MD/PhD, Stanford University School of Medicine
Craig Jordan, PhD, University of Rochester Medical Center
Chapter 12: Epigenetic Control and Chromosomal Instability
Laurie Jackson-Grusby, PhD, Children's Hospital, Harvard Medical School
Kornelia Polyak, MD/PhD, Dana-Farber Cancer Institute
Bradley Bernstein, MD/PhD, Mass General Hospital, Harvard Medical School
Stephen Baylin, MD, Johns Hopkins School of Medicine
Chapter 13: Signaling Pathways
Roeland Nusse, PhD, Stanford University
Andreas Androutsellis-Theotokis, PhD, National Institute of Health
Ivan Maillard, PhD, University of Pennsylvania School of Medicine
Tannishtha Reya, PhD, Duke University Medical Center
Linheng Li, Stowers, PhD, Institute for Medical Research
Chapter 14: Targeting Cancer Stem Cells: A New Therapeutic Approach
Tessa Holyoake, PhD, University of Glasgow
D. Gary Gilliland, MD/PhD, Howard Hughes Medical Institute
Jeffrey Molldrem, MD, M. D. Anderson Cancer Center
Vera Donnenberg, PhD, McGowan Institute for
「Nielsen BookData」 より